PEN gains CE Mark in Europe for THUNDERBOLT, expanding stroke treatment access and advancing its global stroke care strategy.
Penumbra (PEN) reported earnings 30 days ago. What's next for the stock?
Penumbra (PEN) came out with quarterly earnings of $0.82 per share, missing the Zacks Consensus Estimate of $1.11 per share. This compares to earnings of $0.83 per share a year ago.
| Health Care Equipment & Supplies Industry | Healthcare Sector | Adam Elsesser CEO | XFRA Exchange | 70975L107 CUSIP |
| US Country | 4,600 Employees | - Last Dividend | 16 Nov 2014 Last Split | 18 Sep 2015 IPO Date |
Penumbra, Inc., together with its subsidiaries, is a healthcare company that specializes in the design, development, manufacture, and marketing of innovative medical devices. The company has a global presence, providing its wide range of products across the United States and internationally. Established in 2004 and based in Alameda, California, Penumbra is committed to improving patient care by offering solutions for various medical conditions, particularly in the fields of thrombectomy and embolization. It operates through direct sales organizations and distributors, making its advanced medical technologies accessible to healthcare professionals around the world.
Penumbra Inc.'s portfolio of medical devices is extensive and caters to several healthcare needs, particularly in vascular and neurovascular therapies. Below is a detailed look at some of their key products and services: